To help close this prevention gap in Florida, a new health platform, WePrevent.org, launched today with a mission to shift ...

BOHEMIA, N.Y., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a developer of digitally simplified bioprocessing products and vision-based pill counters, announced it will ...

The webcast will take place at 9:30 a.m. ET on Tuesday, August 19, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/cts2025/ or directly at ...

Photo: Founder and Chief Dentist Dr. Mehmet İşlek of Attelia Dental Clinic receiving the Quality Choice Prize 2025 award.

The Company’s bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at ...

“This donation is a small way to express my admiration for Opportunity Project’s work and its impact on so many lives,” said Dr. Saadi. “As a fellow New Jersey organization, we share a deep commitment ...

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his ...

Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate ...

The Company remains on track to initiate the HCW9302 clinical trial in the third quarter of 2025. This trial is a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug ...

Iovance is investigating Amtagvi in frontline advanced melanoma in the Phase 3 trial, TILVANCE-301 (NCT05727904), as well as in additional solid tumor types. About Iovance Biotherapeutics, Inc.

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Gross margin expanded by 208 basis points to 7.89% in Q2 2025, compared to 5.81% in Q2 2024, and for the first half of 2025 gross margin expanded by 374 basis points to 11.30%, compared to 7.56% in ...